Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib

Leukemia

Volumn 28, Issue 2, 2014, Pages 449-451

  Massa, M ^a   Rosti, V ^a,b   Campanelli, R ^a,b   Fois, G ^a,b   Barosi, G ^a,b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 7 RECEPTOR; RUXOLITINIB; TRANSCRIPTION FACTOR FOXP3;

CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HUMAN; LETTER; LYMPHOCYTE FUNCTION; MYELOFIBROSIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

CD4 LYMPHOCYTE COUNT; HUMANS; JANUS KINASES; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 84893773351     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.296     Document Type: Letter

References (17)

1. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in under standing and management of myeloproliferative neoplasms. CA Cancer J Clin 2009; 59: 171-191.
2. Barosi G, Magrini U, Gale RP. Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis? Leuk Res 2010; 34: 1119-1120.
3. Kristinsson SY, Landgren O, Samuelsson J, Bjorkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 2010; 95: 1216-1220.
4. Pardanani A. Ruxolitinib for myelofibrosis therapy:current context, pros and cons. Leukemia 2012; 26: 1449-1451.
5. Colomba C, Rubino R, Siracusa L, Lalicata F, Trizzino M, Titone L et al. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes 2012; 5: 552.
6. JAKAVI [Summary of Product Characteristics] Novartis Pharma AG: Basel, Switzerland, 2012.
7. Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest 2013; 143: 1478-1479.
8. Caocci G, Murgia F, Podda L, Solinas A, Atzeni S, Nasa GL. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 2014; 28: 225-227.
9. Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib [letter]. N Engl J Med 2013; 369: 681-683.
10. Wathers R, Moule S, Milojkovic D. Progressive multifocal leukoencephalopathy associated with ruxolitinib [letter]. N Engl J Med 2013; 369: 197-198.
11. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010; 11: 7-13.
12. Murawski MR, Litherland SA, Clare-Salzler MJ, Davoodi-Semiromi A. Upregulation of Foxp3 expression in mouse and human Treg is IL-2/STAT5 dependent: implications for the NOD STAT5B mutation in diabetes pathogenesis. Ann N Y Acad Sci 2006; 1079: 198-204.
13. Zeiser R, Negrin RS. Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle 2008; 7: 458-462.
14. Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007; 21: 1658-1668.
15. Hart S, Goh KG, Novotny-Diermayr V, Hu CY, Hentze H, Tan YC et al. SB1518, a novelmacrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 2011; 25: 1751-1759.
16. Rowe JH, Ertelt JM, Way SS. Foxp3 regulatory cells, immune stimulation and host defence against infection. Immunology 2011; 136: 1-10.
17. Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 2013; 122: 1192-1202.